USPTO backs WARF stem cell patents


Eileen McDermott, New York and Eklavya Gupte, London 

The Wisconsin Alumni Research Foundation (WARF) was celebrating last month after the USPTO issued favourable decisions on three controversial patent applications for stem cells. But two public interest groups who challenged the patents have vowed to fight the latest rulings.

Last month, the PTO approved amended applications for two of the patents (numbers 5,843,780 and 6,200,806), which claim preparations of, respectively, primate and human embryonic stem cells and methods for their isolation. In a separate decision, on February 23, a third patent (number 7,029,913) was upheld by the PTO following an obviousness challenge.

The technology in all three patents was developed by the scientist who established the...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Simon Brown of Adams & Adams- Chinese investment into Africa about double that of the US's.

Sep 3 2014 06:29 ·  reply ·  retweet ·  favourite
ManagingIP profile

Tom Wimbiscus of McAndrews Held Malloy- typical ITC protective order may not be enough to protect client info. #MIPShanghai

Sep 3 2014 05:59 ·  reply ·  retweet ·  favourite
ManagingIP profile

Patrice Durand of Valipat discussing patent life cycle and which parts are prime for commodification. #MIPShanghai http://t.co/6WhIMMYOga

Sep 3 2014 03:02 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


September 2014

The surprising rise of the PTAB

Patent owners have been shocked at how popular IPR proceedings at the PTAB have proven. As the USPTO mulls over changes and the Federal Circuit braces itself for a deluge of appeals, Michael Loney reports on how the PTAB is likely to evolve



Most read articles

Supplements